Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Common Equity (2016 - 2025)

Vanda Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $327.2 million for Q4 2025.

  • For Q4 2025, Common Equity fell 39.25% year-over-year to $327.2 million; the TTM value through Dec 2025 reached $327.2 million, down 39.25%, while the annual FY2025 figure was $327.2 million, 39.25% down from the prior year.
  • Common Equity for Q4 2025 was $327.2 million at Vanda Pharmaceuticals, down from $466.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $544.9 million in Q4 2023 and bottomed at $327.2 million in Q4 2025.
  • The 5-year median for Common Equity is $511.4 million (2025), against an average of $504.2 million.
  • The largest annual shift saw Common Equity rose 12.31% in 2021 before it tumbled 39.25% in 2025.
  • A 5-year view of Common Equity shows it stood at $504.9 million in 2021, then increased by 4.41% to $527.2 million in 2022, then grew by 3.36% to $544.9 million in 2023, then fell by 1.17% to $538.5 million in 2024, then crashed by 39.25% to $327.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Common Equity are $327.2 million (Q4 2025), $466.0 million (Q3 2025), and $486.3 million (Q2 2025).